Navigation Links
HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
Date:4/25/2011

nd biologic effects on fetal hemoglobin induction and red blood cell production in the laboratory, relevant animal models, and in clinical trials carried out in healthy human subjects as well as patients with sickle cell disease and beta thalassemia. The compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia.

ABOUT SICKLE CELL DISEASE Sickle cell disease is a genetic blood disorder that affects approximately 110,000 patients in the U.S. and Europe and 250,000 in the Middle East. Sickle cell disease is characterized by production of an abnormal beta hemoglobin chain of adult hemoglobin, which results in distorted, rigid sickle red blood cells, which block blood vessels, causing lack of oxygen to tissues, acute episodes of pain (pain crises), lung injury (acute chest syndrome), and strokes. Infections are common, and chronic damage occurs in many organs, including the spleen, bones, kidneys, lungs, brain, and eyes. The sole drug which is approved to treat the disease is a cancer chemotherapy drug, hydroxyurea.  The lifespan of sickle cell patients is markedly reduced.

ABOUT HEMAQUEST PHARMACEUTICALS, INC.HemaQuest Pharmaceuticals (www.HemaQuest.com), established in late 2007, is a San Diego and Seattle-based biopharmaceutical company focused on developing small molecule therapeutics based on its proprietary SCFAD technologies to treat hemoglobin diseases. HemaQuest is also developing a proprietary multi-drug therapeutic approach for treating viral-associated malignancies, with a primary focus on Epstein-Barr virus associated lymphomas. The Company's investors include De Novo Ventures, Forward Ventures, Lilly Ventures, Aberdare Ventures and Latterell Venture Partners.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective f
'/>"/>

SOURCE HemaQuest Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
2. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
3. HemaQuest Pharmaceuticals, Inc. Presents Promising Clinical Results at 52nd Annual Meeting of the American Society of Hematology (ASH)
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)...  The fairness of the proposed acquisition of Thoratec ... ("St. Jude") is the subject of an investigation by ... firm.  The investigation is focusing on possible breaches of ... Board of Directors of THOR for agreeing to sell ... Company announced it had reached a definitive agreement for ...
(Date:7/27/2015)... BOULDER, Colo. , July 27, 2015 ... will report financial results for the fourth ... and hold a conference call to discuss ... Ron Squarer, Chief Executive Officer will lead ... 2015Time:9:00 a.m. Eastern TimeToll-Free:(844) 464-3927Toll:(765) 507-2598Pass Code: ...
(Date:7/27/2015)... As per the new market report ... Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2021," ... 2014, growing at a CAGR of 13.2% from 2015 to ... The global bionics market is growing primarily due to ... to paralysis or amputation of body parts. In addition, increasing ...
Breaking Medicine Technology:WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4
... SCHAUMBURG, Ill., Sept. 30 Sagent Pharmaceuticals, Inc., ... that it has launched vinorelbine injection, USP, an ... of vinorelbine injection, USP in the United States ... shipping vinorelbine injection immediately. , "Sagent has launched ...
... ROCKLAND, Mass., Sept. 30 EMD Serono, ... today the submission of a New Drug Application (NDA) ... Cladribine Tablets, EMD Serono,s proprietary investigational oral formulation of ... with relapsing forms of multiple sclerosis (MS). Cladribine Tablets ...
Cached Medicine Technology:Sagent Pharmaceuticals Launches Vinorelbine Injection, USP 2EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 2EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 3EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 4
(Date:7/27/2015)... Lexington, Kentucky (PRWEB) , ... July 28, 2015 ... ... KORT (Kentucky Orthopedic Rehab Team) as the sports medicine provider for the entire ... (ACHS). , According to ACHS Athletic Director Rick Sallee, “Student safety and ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association ... 2015 Professional Woman of the Year. Ms. Baum-Lappe is recognized with this prestigious ... women in the country, spanning virtually every industry and profession, the National Association ...
(Date:7/27/2015)... ... 27, 2015 , ... In a piece published July 22 on ... surgery and explained why people should not shy away from their own personal aspirations. ... the few and celebrate it for the modern wonder that it is.” This is ...
(Date:7/27/2015)... ... ... The Maricopa Community Colleges today announced a new program that ... into and complete college. , The “Bridging Success Initiative,” funded by the ... from across the valley. , The initiative advisory board has representatives from Arizona State ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ... hiking to its options. Already an industry leader because of its use ... lookout for the latest successful trends in helping people to overcome addiction and ...
Breaking Medicine News(10 mins):Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 2Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 3Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... new class of drugs based on a widely used ... the laboratory and in mice, according to researchers. The ... treatment of these tumors. // ,Previous drugs ... same cell targets as hydroxyurea, but had serious side ...
... mantra of the media as dozens of people exposed to ... potent antibiotic. But if the supply dwindles, doctors say other ... previous generation's wonder drug: penicillin. Although alternatives exist, Cipro is ... , // ,It helped that Cipro was the ...
... An experimental anti-cancer drug has shown effectiveness in treating ... report. Researchers say the drug probably acts on many ... for treating other types of cancer. Dr. Antonio Fojo ... colleagues tested the drug, depsipeptide//, in patients with T-cell ...
... virus that kills at least 30 percent of its ... the globe more than two decades ago. Scientists retained ... and stored them in secure laboratories in Atlanta, Georgia, ... of many potential bioterrorism threats, but "perhaps it is ...
... warned doctors that doxycycline -- an antibiotic being prescribed ... -- can stunt fetal growth when taken by pregnant ... urged doctors to prescribe Cipro to pregnant women. The ... being overprescribed in the general population, possibly causing common ...
... drugs, statements about drug benefits are often overblown ... expected benefit; instead, they make an emotional appeal," ... New Hampshire. // ,Instead of telling ... medicine is going to prevent some outcome, these ...
Cached Medicine News:
... EXPRESS Seeding Cartridge System is a single-use, ... seeds and spacers into a Bard BrachyStar ... has a(n): outer radiation safety shield, inner ... spacers, integrally molded fitting that connects the ...
... Luna is a very easy to use ... in close co-operation with practising urologists as ... lower urinary tract dysfunctions. The system offers ... and flow during a natural bladder filling, ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... Dorado™ will exceed your expectations with ... flexible enough to be customized to meet ... your needs grow, Dorado™ can be upgraded ... such as video and database management, it ...
Medicine Products: